BioPharma Dive April 24, 2024
The funds will advance an idiopathic pulmonary fibrosis medicine once owned by Eli Lilly and an antibody-drug conjugate the startup licensed from another biotech.
Endeavor BioMedicines has raised $132.5 million in a Series C round designed to advance its two experimental medicines deeper into clinical testing, the San Diego company announced Wednesday.
The round was led by AyurMaya, an affiliate of investment firm Matrix Capital Management. Originally, the company’s financing target was between $75 million and $100 million, according to CEO John Hood. But Endeavor upped its expectations after reaching out to investors late last year.
Hood and his team found strong interest in a biotech with two drugs in early- and mid-stage testing, suggestive of the current investment climate...
Today's Sponsors
Today's Sponsor